BACKGROUND: An effective NMDA antagonist imaging model may find key utility in advancing schizophrenia drug discovery research. We investigated effects of subchronic treatment with the NMDA antagonist memantine by using behavioural observation and multimodal MRI. METHODS: Pharmacological MRI (phMRI) was used to map the neuroanatomical binding sites of memantine after acute and subchronic treatment. Resting state fMRI (rs-fMRI) and diffusion MRI were used to study the changes in functional connectivity (FC) and ultra-structural tissue integrity before and after subchronic memantine treatment. Further corroborating behavioural evidences were documented. RESULTS: Dose-dependent phMRI activation was observed in the prelimbic cortex following acute doses of memantine. Subchronic treatment revealed significant effects in the hippocampus, cingulate, prelimbic and retrosplenial cortices. Decreases in FC amongst the hippocampal and frontal cortical structures (prelimbic, cingulate) were apparent through rs-fMRI investigation, indicating a loss of connectivity. Diffusion kurtosis MRI showed decreases in fractional anisotropy and mean diffusivity changes, suggesting ultra-structural changes in the hippocampus and cingulate cortex. Limited behavioural assessment suggested that memantine induced behavioural effects comparable to other NMDA antagonists as measured by locomotor hyperactivity and that the effects could be reversed by antipsychotic drugs. CONCLUSION: Our findings substantiate the hypothesis that repeated NMDA receptor blockade with nonspecific, noncompetitive NMDA antagonists may lead to functional and ultra-structural alterations, particularly in the hippocampus and cingulate cortex. These changes may underlie the behavioural effects. Furthermore, the present findings underscore the utility and the translational potential of multimodal MR imaging and acute/subchronic memantine model in the search for novel disease-modifying treatments for schizophrenia.
BACKGROUND: An effective NMDA antagonist imaging model may find key utility in advancing schizophrenia drug discovery research. We investigated effects of subchronic treatment with the NMDA antagonist memantine by using behavioural observation and multimodal MRI. METHODS: Pharmacological MRI (phMRI) was used to map the neuroanatomical binding sites of memantine after acute and subchronic treatment. Resting state fMRI (rs-fMRI) and diffusion MRI were used to study the changes in functional connectivity (FC) and ultra-structural tissue integrity before and after subchronic memantine treatment. Further corroborating behavioural evidences were documented. RESULTS: Dose-dependent phMRI activation was observed in the prelimbic cortex following acute doses of memantine. Subchronic treatment revealed significant effects in the hippocampus, cingulate, prelimbic and retrosplenial cortices. Decreases in FC amongst the hippocampal and frontal cortical structures (prelimbic, cingulate) were apparent through rs-fMRI investigation, indicating a loss of connectivity. Diffusion kurtosis MRI showed decreases in fractional anisotropy and mean diffusivity changes, suggesting ultra-structural changes in the hippocampus and cingulate cortex. Limited behavioural assessment suggested that memantine induced behavioural effects comparable to other NMDA antagonists as measured by locomotor hyperactivity and that the effects could be reversed by antipsychotic drugs. CONCLUSION: Our findings substantiate the hypothesis that repeated NMDA receptor blockade with nonspecific, noncompetitive NMDA antagonists may lead to functional and ultra-structural alterations, particularly in the hippocampus and cingulate cortex. These changes may underlie the behavioural effects. Furthermore, the present findings underscore the utility and the translational potential of multimodal MR imaging and acute/subchronic memantine model in the search for novel disease-modifying treatments for schizophrenia.
Authors: Kathleen A Williams; Matthew Magnuson; Waqas Majeed; Stephen M LaConte; Scott J Peltier; Xiaoping Hu; Shella D Keilholz Journal: Magn Reson Imaging Date: 2010-04-24 Impact factor: 2.546
Authors: E A Hackler; N E Byun; C K Jones; J M Williams; R Baheza; S Sengupta; M D Grier; M Avison; P J Conn; J C Gore Journal: Neuroscience Date: 2010-03-27 Impact factor: 3.590
Authors: Stephen M Lawrie; Christian Buechel; Heather C Whalley; Christopher D Frith; Karl J Friston; Eve C Johnstone Journal: Biol Psychiatry Date: 2002-06-15 Impact factor: 13.382
Authors: Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven Journal: Hum Brain Mapp Date: 2017-02-01 Impact factor: 5.038
Authors: Emily L Newman; Miho Terunuma; Tiffany L Wang; Nishani Hewage; Matthew B Bicakci; Stephen J Moss; Joseph F DeBold; Klaus A Miczek Journal: Neuropsychopharmacology Date: 2017-10-20 Impact factor: 7.853
Authors: Milou Straathof; Erwin L A Blezer; Christel E Smeele; Caroline van Heijningen; Annette van der Toorn; Jan K Buitelaar; Jeffrey C Glennon; Willem M Otte; Rick M Dijkhuizen Journal: Psychopharmacology (Berl) Date: 2022-04-14 Impact factor: 4.415
Authors: Sylvia Josephy-Hernandez; Iulia Pirvulescu; Mario Maira; Tahar Aboulkassim; Tak Pan Wong; R Anne McKinney; H Uri Saragovi Journal: PLoS One Date: 2019-06-24 Impact factor: 3.240
Authors: Will Penny; Jorge Iglesias-Fuster; Yakeel T Quiroz; Francisco Javier Lopera; Maria A Bobes Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472